Tirzepatide (Zepbound) Should Be Stopped 4 Weeks Before Elective Surgery
For elective surgery requiring general anesthesia, stop tirzepatide (Zepbound) 4 weeks (28 days) before the procedure to minimize aspiration risk. This recommendation is based on tirzepatide's elimination half-life of 5 days and the need to allow approximately 5-6 half-lives for complete drug clearance 1.
Rationale Based on Pharmacokinetics
Tirzepatide has distinct pharmacokinetic properties that inform the preoperative holding period:
- Elimination half-life: 5 days 1
- Time to complete clearance: ~25-30 days (5-6 half-lives)
- Weekly dosing schedule creates sustained drug exposure
The 2025 multidisciplinary consensus from the Association of Anaesthetists and multiple UK specialty societies explicitly addresses GLP-1/GIP receptor agonists like tirzepatide, noting that weekly formulations require longer discontinuation periods than daily formulations 1.
The Aspiration Risk Context
The primary concern driving this recommendation is delayed gastric emptying leading to pulmonary aspiration:
- Studies show an odds ratio of 10.23 (95% CI: 2.94-35.82) for aspiration risk in elective surgery with GLP-1 RA use 1
- The European Medicines Agency Pharmacovigilance Risk Assessment Committee has highlighted delayed gastric emptying as a class effect 1
- While tachyphylaxis may reduce this effect with long-term use, the magnitude of residual risk remains uncertain 1
Practical Implementation Algorithm
Step 1: Identify the surgery date
- Schedule elective procedures to allow 4 weeks off medication
Step 2: Calculate the last dose
- Last tirzepatide injection should be 28 days before surgery
- If patient is on weekly dosing, this means skipping 4 consecutive doses
Step 3: Consider the indication
- For diabetes: Coordinate with endocrinology for alternative glycemic control during the holding period
- For obesity: Weight management can be temporarily paused; the metabolic benefits are durable enough to withstand a 4-week interruption
Step 4: Document the plan
- Clearly communicate the holding period to the patient, surgeon, and anesthesiologist
- Ensure anesthesia team is aware even if medication is held appropriately
Important Caveats
Urgent/emergent surgery: If surgery cannot be delayed, proceed with aspiration precautions including rapid sequence intubation and consider point-of-care gastric ultrasound to assess gastric contents 1.
Metabolic considerations: While stopping tirzepatide may lead to temporary glycemic deterioration or weight regain, the mortality risk from aspiration pneumonitis outweighs these concerns in the elective setting 1.
Resumption after surgery: Tirzepatide can typically be restarted once oral intake is established and there are no ongoing gastrointestinal complications, usually 1-2 weeks postoperatively depending on the procedure.
Comparison to Other GLP-1 RAs
For context, the American Society of Anesthesiologists recommends:
- Daily GLP-1 RAs: Hold 1 day before surgery
- Weekly GLP-1 RAs: Hold 1 week before surgery 1
However, tirzepatide's longer 5-day half-life compared to other weekly agents (e.g., semaglutide: 7 days but different volume of distribution) justifies the extended 4-week holding period to ensure adequate drug clearance 1.